KR101310511B1 - 흉선-특이성 단백질 - Google Patents

흉선-특이성 단백질 Download PDF

Info

Publication number
KR101310511B1
KR101310511B1 KR1020077011700A KR20077011700A KR101310511B1 KR 101310511 B1 KR101310511 B1 KR 101310511B1 KR 1020077011700 A KR1020077011700 A KR 1020077011700A KR 20077011700 A KR20077011700 A KR 20077011700A KR 101310511 B1 KR101310511 B1 KR 101310511B1
Authority
KR
South Korea
Prior art keywords
peptide
disease
seq
cells
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077011700A
Other languages
English (en)
Korean (ko)
Other versions
KR20070097423A (ko
Inventor
요람 드바리
우지엘 샌들러
Original Assignee
임뮨 시스템 키 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 임뮨 시스템 키 리미티드 filed Critical 임뮨 시스템 키 리미티드
Publication of KR20070097423A publication Critical patent/KR20070097423A/ko
Application granted granted Critical
Publication of KR101310511B1 publication Critical patent/KR101310511B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
KR1020077011700A 2004-10-25 2005-10-26 흉선-특이성 단백질 Expired - Lifetime KR101310511B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62108604P 2004-10-25 2004-10-25
US60/621,086 2004-10-25
PCT/IL2005/001113 WO2006046239A2 (en) 2004-10-25 2005-10-26 A thymus-specific protein

Publications (2)

Publication Number Publication Date
KR20070097423A KR20070097423A (ko) 2007-10-04
KR101310511B1 true KR101310511B1 (ko) 2013-09-25

Family

ID=36204363

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077011700A Expired - Lifetime KR101310511B1 (ko) 2004-10-25 2005-10-26 흉선-특이성 단백질

Country Status (12)

Country Link
US (1) US8071716B2 (enExample)
EP (1) EP1809660B1 (enExample)
JP (1) JP5036546B2 (enExample)
KR (1) KR101310511B1 (enExample)
CN (1) CN101080420A (enExample)
AU (1) AU2005298245B2 (enExample)
CA (1) CA2585364C (enExample)
DK (1) DK1809660T3 (enExample)
ES (1) ES2507094T3 (enExample)
IL (1) IL182771A0 (enExample)
RU (2) RU2535971C2 (enExample)
WO (1) WO2006046239A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007091240A2 (en) * 2006-02-06 2007-08-16 Immune System Key Ltd. Treatment of immunological diseases
WO2007122622A1 (en) * 2006-04-24 2007-11-01 Immune System Key Ltd. Method of treatment of a disease
US20100204097A1 (en) * 2006-12-18 2010-08-12 Immune System Key Ltd. Therapeutic methods using a thymus peptide
IL199618A0 (en) 2009-06-29 2010-04-29 Two To Biotech Ltd Novel antibodies and their use in diagnostic methods
CN202856488U (zh) 2012-08-03 2013-04-03 埃塞克科技有限公司 横向磁通发电机
CA2827650A1 (en) 2012-09-24 2014-03-24 Eocycle Technologies Inc. Transverse flux electrical machine stator and assembly thereof
CA2829812A1 (en) 2012-10-17 2014-04-17 Eocycle Technologies Inc. Transverse flux electrical machine rotor
US9878015B2 (en) 2013-12-05 2018-01-30 Immune System Key Ltd. Pharmaceutical compositions and methods for the treatment of metastatic cancer
WO2015105905A1 (en) * 2014-01-09 2015-07-16 Cmi Research Management, Llc Treating gingivostomatitis and demodectic mange
US10842819B2 (en) 2014-01-09 2020-11-24 Cmi Research Management, Llc Compositions and methods for treating itching, gingivostomatitis, and demodectic mange
CN116688096A (zh) 2016-02-04 2023-09-05 免疫系统密钥有限公司 在癌症疗法作为预测工具的内质网应激和用于癌症治疗的联合疗法
CA3196886A1 (en) 2020-11-04 2022-05-12 Yoram Devary Polypeptides for use in the treatment and prevention of neurodegenerative diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001557A2 (en) * 1996-07-05 1998-01-15 Schering Corporation Mammalian chemokine reagents
WO2004005318A2 (en) * 2002-07-03 2004-01-15 Bio Science International, Inc. Peptides comprising aromatic d-amino acids and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2176517C2 (ru) * 1996-07-30 2001-12-10 Санкт-Петербургский государственный университет Комплекс природных катионных белков и способ его получения
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001557A2 (en) * 1996-07-05 1998-01-15 Schering Corporation Mammalian chemokine reagents
WO2004005318A2 (en) * 2002-07-03 2004-01-15 Bio Science International, Inc. Peptides comprising aromatic d-amino acids and methods of use

Also Published As

Publication number Publication date
KR20070097423A (ko) 2007-10-04
RU2007119376A (ru) 2008-11-27
ES2507094T3 (es) 2014-10-14
WO2006046239A2 (en) 2006-05-04
RU2010120571A (ru) 2011-11-27
US20090018060A1 (en) 2009-01-15
AU2005298245A1 (en) 2006-05-04
JP2008517998A (ja) 2008-05-29
JP5036546B2 (ja) 2012-09-26
RU2535971C2 (ru) 2014-12-20
WO2006046239A3 (en) 2006-07-13
IL182771A0 (en) 2007-07-24
US8071716B2 (en) 2011-12-06
CA2585364A1 (en) 2006-05-04
WO2006046239B1 (en) 2006-08-24
DK1809660T3 (da) 2014-10-20
EP1809660A2 (en) 2007-07-25
CN101080420A (zh) 2007-11-28
AU2005298245B2 (en) 2011-03-10
EP1809660B1 (en) 2014-07-23
RU2398776C2 (ru) 2010-09-10
CA2585364C (en) 2014-05-13

Similar Documents

Publication Publication Date Title
JP5651583B2 (ja) 自己免疫疾患の治療および／または予防のための薬剤、ならびに制御性ｔ細胞形成のための薬剤
CN100558745C (zh) 同种排斥反应的特异性抑制
US11124557B2 (en) High-affinity and soluble PDL-1 molecule
WO2020103777A1 (zh) 白介素21蛋白(il21)突变体及其应用
JP2013512200A (ja) Ｉｌ−２に由来する免疫調節ポリペプチド並びに癌及び慢性感染症の治療におけるその使用
KR20010072112A (ko) 암 억제 유전자 더블유티1의 생산물에 기초한 암항원
JPS60252496A (ja) 新規なヒト生理活性ポリペプチド
JPS62501470A (ja) 腫瘍壊死因子の精製、製造および使用法
KR101310511B1 (ko) 흉선-특이성 단백질
CN113336829A (zh) 靶向anp32a抗白血病的小分子肽及其制备方法和应用
KR100692226B1 (ko) 신규 폴리펩티드, 그 폴리펩티드를 암호화하는 ｃＤＮＡ 및 그 용도
KR20010043090A (ko) 신규인 폴리펩티드, 그 폴리펩티드를 코드화하는 ｃＤＮＡ및 그 용도
KR101025352B1 (ko) 생리활성 복합체
EP1252897A1 (en) Drugs for gene therapy
CA3133147A1 (en) Core master regulators of glioblastoma stem cells
CN110105442B (zh) 一种具有抗肿瘤作用的宿主因子hPRDX5、编码基因及其应用
CN100480264C (zh) 一种广谱抑制癌细胞生长的蚯蚓蛋白及其编码序列
CN101017166A (zh) 人rtn4b蛋白在制备抗肿瘤药物中的应用
WO2025101551A1 (en) Prostate-specific membrane antigen (psma)-binding peptides and method of use
KR20130011056A (ko) 염증표적 수용체 및 염증 질환 치료용 약물 운반체
CN101289505A (zh) 骨髓再生调控蛋白brrg-2、其编码基因及其应用
JP2001512449A (ja) 細胞増殖を阻害するペプチド及びその使用
CN101289504A (zh) 骨髓再生调控蛋白brrg-1、其编码基因及其应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070523

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20101026

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120815

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130429

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120815

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20130515

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20130429

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20130624

Appeal identifier: 2013101003636

Request date: 20130515

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20130515

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20130515

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20121214

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20101026

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20130624

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20130617

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20130912

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20130912

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20160909

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20160909

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20170908

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20170908

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20180828

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20180828

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20190905

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20190905

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20200819

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20210818

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20240729

Start annual number: 12

End annual number: 12